Publications & Data Briefs

Showing: 33 – 40 of 71
PAs and Buprenorphine Waivers cover

PAs and Buprenorphine Waivers

Substance use disorder and opioid use disorder (SUD and OUD) are widespread. Substance and opioid use disorders do not discriminate. PAs in every setting and specialty are likely to encounter a patient who may potentially be struggling with SUD or OUD. Medication-assisted treatments (MAT) approved to potentially combat OUD and SUD. Include the usage of medication in conjunction with counseling and/or behavioral therapies to treat substance use disorder.

PA Use of Telemedicine in June 2020

PAs Use of Telemedicine in June 2020

Results from the June 2020 PA Practice Survey illustrate the integration of telehealth into the practice of PAs, as of June 2020.

Insights into the PA Experience During COVID-19

Insights into the PA Experience During COVID-19

Results from the August 2020 PA Practice Survey represent all individuals eligible to practice as PAs. These data illustrate the status of the PA profession six months into the COVID-19 pandemic. During this time period, there has been a rapid expansion of telehealth and concerns with PAs’ and patients’ well-being.

COVID-19 and the PA Workforce cover

AAPA’s New National Survey of PAs During COVID-19 Crisis

Results from this PA Pulse Survey focused on clinically practicing PAs on the frontlines of COVID-19. It shows the considerable contributions of PAs and the scale at which they have had to adapt to meet the needs of patients during the COVID-19 crisis. It is the first effort to quantify the experiences of these frontline medical providers.